Search results
Author(s):
Robert Mentz
Added:
1 year ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more
Author(s):
Paul Kalra
Added:
1 year ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and…
View more
Advancements in Triglyceride-lowering Therapies
Video Series
Tricuspid Regurgitation Therapy
Author(s):
Qiuyu Martin Zhu
,
Natalia Berry
Added:
1 year ago
Article
Author(s):
Jason G Andrade
Added:
1 year ago
Author(s):
Amish Raval
Added:
1 month ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the…
View more
Author(s):
Massimiliano Camilli
,
Luca Maggio
,
Lorenzo Tinti
,
et al
Added:
1 month ago
Author(s):
Christophe Leclercq
Added:
1 month ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire…
View more
Author(s):
Milind Y Desai
Added:
1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Author(s):
Harriette Van Spall
,
Kausik Ray
Added:
5 months ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising…
View more